JP2023508325A5 - - Google Patents

Info

Publication number
JP2023508325A5
JP2023508325A5 JP2022538213A JP2022538213A JP2023508325A5 JP 2023508325 A5 JP2023508325 A5 JP 2023508325A5 JP 2022538213 A JP2022538213 A JP 2022538213A JP 2022538213 A JP2022538213 A JP 2022538213A JP 2023508325 A5 JP2023508325 A5 JP 2023508325A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical product
aforementioned
product according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508325A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065408 external-priority patent/WO2021127043A1/en
Publication of JP2023508325A publication Critical patent/JP2023508325A/ja
Publication of JP2023508325A5 publication Critical patent/JP2023508325A5/ja
Pending legal-status Critical Current

Links

JP2022538213A 2019-12-20 2020-12-16 組み合わせ Pending JP2023508325A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952114P 2019-12-20 2019-12-20
US62/952,114 2019-12-20
US202063009758P 2020-04-14 2020-04-14
US63/009,758 2020-04-14
PCT/US2020/065408 WO2021127043A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (2)

Publication Number Publication Date
JP2023508325A JP2023508325A (ja) 2023-03-02
JP2023508325A5 true JP2023508325A5 (cg-RX-API-DMAC7.html) 2023-12-25

Family

ID=76478082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538213A Pending JP2023508325A (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230053946A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069225A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023508325A (cg-RX-API-DMAC7.html)
KR (1) KR20220119657A (cg-RX-API-DMAC7.html)
CN (1) CN115023224A (cg-RX-API-DMAC7.html)
AU (1) AU2020407572A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012266A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165382A1 (cg-RX-API-DMAC7.html)
IL (1) IL294068A (cg-RX-API-DMAC7.html)
MX (1) MX2022007627A (cg-RX-API-DMAC7.html)
TW (1) TW202142234A (cg-RX-API-DMAC7.html)
WO (1) WO2021127043A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用
CN119524139A (zh) * 2023-08-28 2025-02-28 海创药业股份有限公司 一种雌激素蛋白靶向降解剂的联合用药物及其用途
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
CN122421961A (zh) * 2023-10-30 2026-07-17 密歇根大学董事会 双重功能免疫调节化合物、其制剂及用途
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
CN119950496B (zh) * 2024-12-24 2025-11-21 华东师范大学 靶向slc7a7的抑制剂在制备治疗肺癌骨转移癌药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39740A (fr) * 2014-03-13 2017-01-18 Hoffmann La Roche Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US20180002344A1 (en) * 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof

Similar Documents

Publication Publication Date Title
JP2023507797A5 (cg-RX-API-DMAC7.html)
Roche et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
JP5424923B2 (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
JP2019529581A5 (cg-RX-API-DMAC7.html)
JP2018514511A5 (cg-RX-API-DMAC7.html)
JP2006512281A (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
RU2019114079A (ru) Лечение er+ рака молочной железы лазофоксифеном
JP2023507799A5 (cg-RX-API-DMAC7.html)
Randall et al. Cytoreductive surgery for ovarian cancer
Curry et al. Second-look laparotomy for ovarian cancer
Takahashi et al. Clinicopathological features of early and late recurrence of endometrial carcinoma after surgical resection
Howell et al. Are aromatase inhibitors superior to antiestrogens?
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
Malik et al. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
CN100408036C (zh) 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途
KR20240073856A (ko) 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료
Alektiar et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I–II serous endometrial cancer
Yousefnia Breast cancer, subtypes, risk factors, and treatment
CN120324434A (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
Hu et al. 5-aza-2’-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy
Bae et al. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B–2B cervical cancer
Vassilomanolakis et al. A phase II study of flutamide in ovarian cancer
Landreat et al. Low-grade endometrial stromal sarcoma of the uterus: review of 10 cases
Di Legge et al. Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer
EP2821071A1 (en) Compounds for breast cancer treatment